Sanmina reported quarterly earnings of $1.53 per share which beat the analyst consensus estimate of $1.42 per share. The ...

Synopsys, Inc. (SNPS) is currently at $646.13, up $53.50 or 9.03% --Would be new all-time high (Based on available data back to Feb. 26, 1992) --Would be the first new record closing high since July 5 ...

Cadence Design Systems (CDNS) tops Q2 expectations, lifts 2025 outlook amid AI-driven demand. Analysts boost price targets; ...

Dental caries remains a significant global public health burden, affecting billions worldwide despite preventive measures. While behavioral and ...

Scottish first minister John Swinney used Donald Trump’s visit to make new promises over a second independence referendum, ...

There's plenty of reason to be optimistic about Synopsys' future; however, whether it could realistically make you a ...

Researchers evaluated the relative importance of phenotypic and genetic factors in predicting risk for head and neck cancer.

The precedent set by the SNP’s 2011 election victory would break the “logjam” towards a second independence referendum, John ...

The Bangladesh Ministry of Health is pushing a new tobacco control bill that proposes a sweeping ban on all safer nicotine products (SNPs), including vaping devices and oral alternatives. Alarmingly, ...

Climate change is significantly affecting forest ecosystems through rising temperatures, altered precipitation patterns, and ...

In the most recent trading session, Synopsys (SNPS) closed at $601.55, indicating a -1.33% shift from the previous trading day.

A nascent hypothesis regarding pulmonary arterial hypertension (PAH) is that there is a link between thyroid dysfunction and PAH risk; much remains to be investigated to prove causality.